Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05039177 · ClinicalTrials.gov registry record · Phase 1

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

A Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Erasca.

Active
Registry status
Phase 1
Development phase
102
Enrollment target
14
Study locations

NCT05039177 is a Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Erasca. The registered enrollment target is 102 participants, below the 184-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (45% lower). The trial reports 14 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05039177, a Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Erasca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
102 participants
Enrollment target
14
Study locations

Study Summary

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Conditions Studied

Metastatic Colorectal Cancer Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Cetuximab
  • DRUG Palbociclib
  • DRUG Encorafenib
  • DRUG ERAS-007

Study Locations (14)

California

  • City of Hope - Duarte
  • University of California Irvine College of Medicine - Orange
  • UCSF Mount Zion Medical Ctr - San Francisco

Alabama

  • University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) - Birmingham

Maryland

  • The Johns Hopkins Hospital - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Henry Ford Cancer Institute - Detroit

Missouri

  • Washington University (Siteman Cancer Center) - St Louis

North Carolina

  • Duke Cancer Institute - Durham

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2021-09-20
Est. Completion 2025-12
Phase Phase 1

Sponsor

Erasca

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05039177

The ClinicalTrials.gov registry entry for NCT05039177 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (45% lower). The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cetuximab is the first listed.

NCT05039177 reports 14 study locations spanning 12 distinct geographic areas - top geographies include California, Alabama, Maryland.

Frequently Asked Questions

What is clinical trial NCT05039177 about?

NCT05039177 is a clinical study titled "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies". * To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other ca...

What is the current status of trial NCT05039177?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2021-09-20. Estimated completion is 2025-12.

What conditions does trial NCT05039177 study?

This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT05039177?

The interventions under investigation include: Cetuximab (DRUG), Palbociclib (DRUG), Encorafenib (DRUG), ERAS-007 (DRUG).

Who is sponsoring clinical trial NCT05039177?

This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05039177 being conducted?

This trial has 14 study locations across Alabama, California, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Colorectal Cancer

All registered trials for this condition

Metastatic Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.